GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment
This article was originally published in The Tan Sheet
Sales exceeding $150 million in two weeks on retail shelves for OTC weight-loss drug alli figure prominently in GlaxoSmithKline's commitment to its consumer health care products division, senior executives say
You may also be interested in...
GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth
Significantly lower sales of GlaxoSmithKline's alli OTC weight-loss drug combined with struggles in the nicotine replacement therapy category weighed down the consumer health care division's performance in the firm's latest quarter
GlaxoSmithKline's over-the-counter product sales posted a 24 percent increase to $854.6 million for the third quarter, driven in by U.S. sales of its alli weight loss drug, the firm said in an Oct. 24 earnings call